GEN Exclusives

More »

GEN News Highlights

More »
Aug 30, 2011

EMD Millipore Signals Expansion into Flow Cytometry with Amnis Acquisition

EMD Millipore Signals Expansion into Flow Cytometry with Amnis Acquisition

Merck KGaA unit acquires $14 million-a-year cell imaging instrumentation maker in deal set to close in Q4.[© Yuri Arcurs -]

  • Signaling a desire to expand within flow cytometry, EMD Millipore announced plans to acquire cell imaging instrumentation maker Amnis for an undisclosed sum. The deal, subject to regulatory approvals, is expected to close in the fourth quarter.

    In acquiring Amnis—which generated $14 million in sales last year, and employs 40 people—EMD Millipore sought a business that would complement its Guava family of products, acquired with their namesake company in 2009. EMD Millipore is the life sciences division of German-owned Merck KGaA.

    Jonathan DiVincenzo, head of EMD Millipore’s bioscience business unit, said that the deal would benefit the company by allowing it to offer a solution combining flow cytometry and image analysis. Amnis is EMD Millipore’s second acquisition this year. In March, it snapped up the microbiology operations of German-owned Biotest.

    “The combination of Amnis with EMD Millipore will greatly accelerate development of novel applications in imaging flow cytometry, enhance our customer support, and accelerate product development,” said David A. Basiji, co-founder and CEO of Amnis.



Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »